Axsome Therapeutics (NASDAQ:AXSM) CEO Herriot Tabuteau Sells 29,450 Shares

January 8, 2026 by InsiderTrades.com

Key Points

CEO Herriot Tabuteau completed large insider sales: he sold 29,450 shares on Jan. 6 for $5.08M and a combined ~139,414 shares across Jan. 5–7 for roughly $23.9M, leaving him with 7,229 shares (about an 80% reduction in his position).
Company fundamentals and analyst backdrop: Axsome has a $8.6B market cap and reported revenue up 63.2% YoY but a negative EPS (missed last quarter), while analysts remain bullish overall (consensus "Moderate Buy" with an average target of $191.88 and several raised price targets).

Axsome Therapeutics, Inc. (NASDAQ:AXSM - Get Free Report) CEO Herriot Tabuteau sold 29,450 shares of the stock in a transaction dated Tuesday, January 6th. The shares were sold at an average price of $172.33, for a total transaction of $5,075,118.50. Following the completion of the sale, the chief executive officer owned 7,229 shares of the company's stock, valued at approximately $1,245,773.57. This trade represents a 80.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out

Herriot Tabuteau also recently made the following trade(s):

On Monday, January 5th, Herriot Tabuteau sold 78,703 shares of Axsome Therapeutics stock. The shares were sold at an average price of $171.28, for a total transaction of $13,480,249.84.
On Wednesday, January 7th, Herriot Tabuteau sold 31,261 shares of Axsome Therapeutics stock. The shares were sold at an average price of $170.38, for a total transaction of $5,326,249.18.
On Thursday, December 4th, Herriot Tabuteau sold 10,558 shares of Axsome Therapeutics stock. The stock was sold at an average price of $148.18, for a total value of $1,564,484.44.
On Tuesday, December 2nd, Herriot Tabuteau sold 49,252 shares of Axsome Therapeutics stock. The shares were sold at an average price of $144.59, for a total transaction of $7,121,346.68.
On Wednesday, December 3rd, Herriot Tabuteau sold 20,163 shares of Axsome Therapeutics stock. The stock was sold at an average price of $146.94, for a total value of $2,962,751.22.
On Tuesday, November 4th, Herriot Tabuteau sold 50,459 shares of Axsome Therapeutics stock. The stock was sold at an average price of $133.79, for a total transaction of $6,750,909.61.
On Wednesday, November 5th, Herriot Tabuteau sold 21,775 shares of Axsome Therapeutics stock. The stock was sold at an average price of $134.49, for a total value of $2,928,519.75.
On Monday, November 3rd, Herriot Tabuteau sold 91,705 shares of Axsome Therapeutics stock. The shares were sold at an average price of $132.34, for a total value of $12,136,239.70.

Axsome Therapeutics Trading Down 0.7%

NASDAQ:AXSM opened at $170.69 on Thursday. The company has a fifty day moving average of $149.54 and a 200 day moving average of $127.07. The firm has a market capitalization of $8.60 billion, a P/E ratio of -36.55, a P/E/G ratio of 9.06 and a beta of 0.44. The company has a quick ratio of 1.50, a current ratio of 1.57 and a debt-to-equity ratio of 1.66. Axsome Therapeutics, Inc. has a 52 week low of $79.19 and a 52 week high of $184.40.

5 medical stocks growing earnings by triple digits

Axsome Therapeutics (NASDAQ:AXSM - Get Free Report) last issued its quarterly earnings data on Monday, November 3rd. The company reported ($0.94) EPS for the quarter, missing the consensus estimate of ($0.82) by ($0.12). The company had revenue of $170.99 million during the quarter, compared to the consensus estimate of $162.96 million. Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The business's revenue was up 63.2% on a year-over-year basis. On average, research analysts predict that Axsome Therapeutics, Inc. will post -2.79 earnings per share for the current year.

Analyst Ratings Changes

Several analysts have recently commented on the stock. HC Wainwright raised their price objective on shares of Axsome Therapeutics from $185.00 to $200.00 and gave the company a "buy" rating in a research report on Monday. Mizuho set a $217.00 price objective on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. Royal Bank Of Canada increased their price target on Axsome Therapeutics from $189.00 to $198.00 and gave the company an "outperform" rating in a report on Tuesday, November 4th. UBS Group upped their target price on Axsome Therapeutics from $163.00 to $248.00 and gave the company a "buy" rating in a research note on Tuesday. Finally, Morgan Stanley reiterated an "overweight" rating on shares of Axsome Therapeutics in a report on Wednesday, December 31st. One research analyst has rated the stock with a Strong Buy rating, eighteen have given a Buy rating and one has issued a Sell rating to the company's stock. According to MarketBeat.com, Axsome Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $191.88.

Struggling Axsome Stock Could Bounce Back on Drug Trial Success

Read Our Latest Stock Analysis on AXSM

Hedge Funds Weigh In On Axsome Therapeutics

Large investors have recently made changes to their positions in the company. GAMMA Investing LLC increased its position in shares of Axsome Therapeutics by 65.4% in the fourth quarter. GAMMA Investing LLC now owns 268 shares of the company's stock valued at $49,000 after buying an additional 106 shares in the last quarter. JPMorgan Chase & Co. raised its holdings in shares of Axsome Therapeutics by 42.6% during the 3rd quarter. JPMorgan Chase & Co. now owns 250,513 shares of the company's stock worth $30,425,000 after acquiring an additional 74,885 shares during the period. Allworth Financial LP lifted its holdings in Axsome Therapeutics by 6.6% in the third quarter. Allworth Financial LP now owns 1,442 shares of the company's stock valued at $175,000 after acquiring an additional 89 shares during the last quarter. CIBC Private Wealth Group LLC boosted its position in shares of Axsome Therapeutics by 5.0% during the 3rd quarter. CIBC Private Wealth Group LLC now owns 14,375 shares of the company's stock worth $1,746,000 after purchasing an additional 686 shares during the period. Finally, CIBC Bancorp USA Inc. acquired a new position in Axsome Therapeutics during the 3rd quarter worth about $524,000. 81.49% of the stock is currently owned by institutional investors and hedge funds.

Key Stories Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

Positive Sentiment: HC Wainwright raised 2026 earnings estimates substantially (Q2, Q3, Q4 and FY2026 to $3.72 EPS total) and reiterated a "Buy" rating with a $200 price target — this signals higher expected profitability and gives investors a near-term target above current levels.
Positive Sentiment: UBS reiterated its Buy rating on AXSM, reinforcing institutional analyst support that can buoy demand for the shares. UBS Sticks to Their Buy Rating for Axsome Therapeutics
Positive Sentiment: Market commentary highlights two late-2025 FDA developments — acceptance of a supplemental filing for AXS-05 (agitation in Alzheimer's) and FDA support for an NDA filing for AXS-12 (narcolepsy). Those regulatory moves expand potential indications and revenue runway, and underpin the bullish analyst view. Biotech Is Heating Up—These 2 Red-Hot Stocks Stand Out
Neutral Sentiment: Street positioning remains overwhelmingly positive (majority of analysts are Buy) and recent reiterations/price targets suggest upside, but consensus still reflects variability in timing and magnitude of revenue from new indications.
Negative Sentiment: CEO insider sales — Herriot Tabuteau sold a combined 139,414 shares across Jan. 5–7 for roughly $23.88M in proceeds; after these trades the CEO directly owns 7,229 shares (a ~90%+ reduction in their position). Large, concentrated insider selling can create near‑term selling pressure and raise governance/optics concerns for some investors. SEC Filing — Insider Transactions

Axsome Therapeutics Company Profile

(Get Free Report)

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome's pipeline includes several late-stage and approved product candidates.